INDEMNIFICATION AGREEMENTIndemnification Agreement • October 8th, 2019 • IMARA Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (“Agreement”) is made as of [ ], 20[ ] by and between IMARA Inc., a Delaware corporation (the “Company”), and [ ] (“Indemnitee”) [[Solely with respect to officers and directors that execute this form of indemnification agreement on or prior to the Company’s initial public offering:] and shall be effective as of the effectiveness of a Registration Statement on Form S-1 relating to the initial registration under the Securities Act of 1933, as amended, of shares of the Company’s common stock].
Imara, Inc. 116 Huntington Ave, 6th Floor Boston, MA 02116 Info@Imaratx.com +1 617 206-2020 www.imaratx.comIMARA Inc. • October 8th, 2019 • Pharmaceutical preparations • Massachusetts
On behalf of IMARA Inc., a Delaware corporation (the “Company”), I am very pleased to offer you this revised “letter agreement” with the Company. This letter agreement shall supersede, amend and restate in all respects the letter agreement between you and the Company dated February 26, 2019, as amended and restated by the letter agreement between you and the Company dated June 27, 2019 (as amended and restated, the “Former Letter Agreement”), provided, and for the avoidance of doubt, that nothing herein supersedes the Employee Confidentiality, Assignment and Noncompetition Agreement signed by you on March 26, 2019 (the “Restrictive Covenants Agreement”), which remains in effect, unaltered, in all respects.
Imara, Inc. Boston, MA 02116 Info@Imaratx.comLetter Agreement • October 8th, 2019 • IMARA Inc. • Pharmaceutical preparations • Massachusetts
On behalf of IMARA Inc., a Delaware corporation (the “Company”), I am very pleased to offer you this revised “letter agreement” with the Company. This letter agreement shall supersede, amend and restate in all respects the letter agreement between you and the Company dated April 17, 2018, as amended and restated by the letter agreement between you and the Company dated August 12, 2019 (as amended and restated, the “Former Letter Agreement”), provided, and for the avoidance of doubt, that nothing herein supersedes the Invention and Non-Disclosure Agreement or the Non-Competition and Non-Solicitation Agreement signed by you concurrently with the Former Letter Agreement (the “Restrictive Covenant Agreements”), which remain in effect, unaltered, in all respects.
